The important question around FormBlends compounded BPC-157 is practical: what is actually known, what remains uncertain, and what safeguards a licensed clinician and pharmacy process add before anyone treats it as an option.
On a Tuesday in November, sitting in a strip-mall orthopedic office in Chandler, Arizona, Dr. Rajan pulled up my second MRI and said something I was ready for but still didn’t want to hear: “You’ve got a partial-thickness supra tear with a labral component. I’d scope it. Six months of rehab after.” My wife, Lauren, was in the waiting room scrolling job listings on her phone. I walked out, told her the number ($4,200 post-deductible, plus PT), and said I wanted to try something else first.
That “something else” was 90 days of subcutaneous BPC-157, logged every single day. This is the full log, with dosing math, injection-site choices, side notes on sleep, and a frank list of what didn’t happen.
A few necessary disclaimers up front. BPC-157 is a research-stage peptide. It is not FDA-approved for any human indication, and the FDA placed it on the 503A bulks list under review in 2023. The version I used was compounded by a licensed 503A pharmacy for an individual patient prescription based on a prescriber’s clinical judgment. None of this is medical advice. It’s a personal log shared in case it helps someone have a more honest conversation with their own doctor.
How I Got Here
I’m 41. Three months before starting the protocol, I tore the supraspinatus tendon in my right shoulder during a deadlift session. Not even a heroic pull. 365 pounds, a weight I’d hit dozens of times. Something slipped in my setup and I felt it unzip.
Two MRIs. Two surgical consults. Partial-thickness tear with a labrum issue stacked on top. Both surgeons recommended arthroscopic repair. I wanted to exhaust conservative options first, and my functional medicine doc had been mentioning BPC-157 for almost a year, mostly in the context of GI work. Research suggests it may modulate growth factors involved in connective tissue repair, but the strongest data lives in rodent models. There is no large randomized human trial. I went in knowing that, and knowing my expectations needed to stay calibrated accordingly.
See also: Gaming Tips TGArchiveTech: Boost Your Skills and Performance
The Protocol, Exactly
I worked with a prescriber who routed the prescription to a 503A compounding pharmacy. The lot came labeled with a beyond-use date and a concentration of 5 mg per 5 mL of bacteriostatic water.
- Dose: 500 mcg subcutaneous, twice daily
- Site: alternating between the abdomen and the deltoid of the injured side
- Duration: 30 days on, 7 days off, 30 days on, 7 days off, 30 days on
- Stacked with: 5 grams of creatine monohydrate, 3 grams of glycine before bed, and a normal whey protein intake of about 1.6 g per kg
I kept everything else stable. No new training stimulus, no new sleep aids, no new anti-inflammatories. The point was to isolate the variable as cleanly as one person doing self-experimentation reasonably can. Think of it like a single-subject case study with all the obvious limitations that implies.
What the Log Actually Shows
Weeks 1 to 2. Almost nothing. The injection itself was painless, a non-event. One day I noticed a small bruise at the abdomen site that I attributed to angling the needle wrong. Shoulder pain at rest: 6 out of 10. Pain on internal rotation: 8. I started wondering if I’d just bought an expensive placebo.
Weeks 3 to 4. First real shift. Rest pain dropped to about a 3. Sleeping on the affected side went from impossible to merely uncomfortable. I was suspicious of my own tracking by this point, watching so closely that I worried I was willing the numbers down. So I had Lauren pull the log without telling me which weeks were on and which were off. She could see the pattern even when I tried to second-guess it.
Weeks 5 to 8. Here’s where I started believing it. Pain on internal rotation came down to a 4. I could reach behind my back to put on a belt without wincing, which sounds trivial until you’ve spent weeks unable to do it. Range of motion in flexion improved from about 140 degrees to 165. I added light banded external rotation work and kept it conservative.
Weeks 9 to 12. Diminishing returns. The improvement curve flattened. I was at maybe 80 percent of pre-injury function. I could overhead press an empty bar without pain. I could not bench press anything heavy without a small ache the next morning. Progress slowed to the point where week 12 looked a lot like week 9.
What Didn’t Happen
This section matters more than the positive one.
I did not heal completely. The MRI at 90 days still showed a partial-thickness tear, though the radiologist noted the surrounding tissue looked less inflamed. I did not get rid of the labrum issue, which still clicks during certain rotations. I did not become a super-healer. I’m not posting before-and-after photos because there is nothing photogenic about a slightly less torn tendon.
I also didn’t have side effects I could clearly attribute to the peptide. No nausea, no injection-site lumps after the second week, no changes in blood pressure or resting heart rate, no changes in fasting glucose or lipids on my next labs. That’s one data point in one person. Extrapolate accordingly, which is to say, don’t.
The Money Part
The 90-day protocol cost me about $480 through the compounding pharmacy, including the prescriber consult. The surgical consult alone would have cost more than that even with insurance. Surgery itself, post-deductible, was estimated at $4,200 plus six months of physical therapy copays.
I’m not making a cost-effectiveness argument. I’m reporting numbers. Whether $480 for an 80-percent functional recovery beats $4,200-plus for a surgical fix depends on variables I can’t quantify for you: your tear severity, your pain tolerance, your job, whether you need to lift a toddler overhead without thinking about it.
Sourcing: The Part Nobody Wants to Talk About
I looked at three different paths, and the differences matter more than most peptide forums acknowledge.
Research-grade powder from an overseas site was the cheapest and the sketchiest. You’re essentially trusting a Certificate of Analysis from a lab you can’t verify, reconstituting powder yourself, and hoping the purity claim is accurate. A US-based research peptide vendor was slightly less sketchy but still labeled “not for human use,” which tells you everything about the legal posture.
A licensed 503A compounding pharmacy with a prescriber relationship was the most expensive option and the only one I felt comfortable injecting. For the second 30-day block I ordered from FormBlends compounded BPC-157 specifically because they’re a US-based compounding pharmacy network that works through a prescriber and ships in lots with beyond-use dating, lot numbers, and a sterility statement. I’m not trying to sell anyone on a brand. I’m sharing what I used so you can ask better questions of your own pharmacist.
Here’s my genuinely opinionated take on sourcing: if you wouldn’t buy injectable insulin from a guy on Reddit, don’t buy injectable peptides that way either. The savings aren’t worth the ambiguity.
How I Think About This Now
If you’re considering BPC-157 for a soft-tissue issue, the best analogy I can offer is this: think of it the way you’d think about buying an expensive piece of physical therapy equipment that has strong rodent data and weak human data. Like a $500 electrical stim unit with promising animal studies and a handful of case reports. It might accelerate recovery. It might do nothing beyond what rest and rehab would have accomplished on their own. It will not regrow a torn tendon to factory spec. The published research is mostly preclinical, and any prescriber who tells you otherwise is selling you something.
The boring truth is that I’m probably going to end up getting the surgery anyway, just from a better starting position. I’m going to run a second 90-day block starting in 30 days, this time pairing BPC-157 with TB-500 for the labrum component. I’ll log that one the same way.
Disclaimer: Not FDA-approved. Compounded peptide therapy is prescribed at the discretion of a licensed medical provider for individual patients based on clinical need. This post reflects one person’s experience and is not medical advice.
Frequently Asked Questions
Is BPC-157 FDA-approved? No. BPC-157 is not FDA-approved for any human indication. The FDA placed it on the 503A bulks list under review in 2023. Any use is off-label and based on a prescriber’s clinical judgment for an individual patient.
What dose of BPC-157 did you use? 500 mcg subcutaneous, twice daily, cycling 30 days on and 7 days off for three total on-cycles (90 days of dosing over roughly 104 calendar days).
Did BPC-157 fully heal your rotator cuff tear? No. At 90 days, the MRI still showed a partial-thickness tear. Pain and range of motion improved significantly, but the structural damage persisted. The radiologist noted reduced inflammation in the surrounding tissue.
Where did you inject BPC-157? I alternated between the abdominal subcutaneous tissue and the deltoid on the injured side. Some practitioners recommend injecting near the injury site; my prescriber was comfortable with either approach.
What did 90 days of BPC-157 cost? Approximately $480, including the prescriber consultation and compounded vials from a licensed 503A pharmacy. This was substantially less than the estimated out-of-pocket surgical cost of $4,200 plus physical therapy.
Is it safe to buy BPC-157 from research peptide vendors? Research peptide vendors sell products labeled “not for human use.” There is no regulatory oversight of purity, sterility, or dosing accuracy for those products. A licensed 503A compounding pharmacy with a prescriber relationship provides labeled lots, beyond-use dating, and sterility documentation.
Can you stack BPC-157 with other peptides? Some practitioners combine BPC-157 with TB-500 (thymosin beta-4) for connective tissue protocols. I did not stack during this first 90-day block but plan to add TB-500 in the next cycle. Any stacking should be discussed with and supervised by a licensed prescriber.
